QYNAPSE is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum (#Sachs_NIF) on April 28-30, 2021. Olivier Courrèges, CEO of QYNAPSE, is pleased to present QYNAPSE’s corporate vision on Day 1 of the Sachs 4th Annual Neuroscience Innovation Forum – which will be held virtually on Wednesday, April 28, 2021 at 2:20 p.m. ET.
QYNAPSE will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The software computes a cognitive decline risk score that can be used to enrich patient selection strategy with the aim to increase clinical trial success probability.
Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS). The latest QyScore® validation and performance advances will be presented during the conference.
Qynapse is thrilled to be part of the Scientific Program of AAIC and the Virtual Exhibition from July 27 to July 31 − to present our latest advances and solutions.
From July 14 – 18th, Qynapse will be part of the 2019 Alzheimer’s Association International Conference® (AAIC®) held in Los Angeles, California
Qynapse took part in the 2019 International Conference on Alzheimer’s & Parkinson’s Disease (AD/PDTM) in Lisbon, Portugal from March 26 – 31st
From July 22– 26th, Qynapse took part in the 2018 Alzheimer’s Association International Conference® (AAIC®) held in Chicago, Illinois
Qynapse is a medical technology company that unlocks the potential of quantitative imaging and AI to optimize diagnosis, prognosis and longitudinal monitoring of patients with neurological diseases.
